Publicaciones (95) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. "What medical students with better academic results do: a cross-sectional analysis"

    BMC medical education, Vol. 23, Núm. 1, pp. 19

  2. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

    Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300

  3. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

  4. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  5. A pharmacometrics model to define docetaxel target in early breast cancer

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 2, pp. 727-736

  6. A simple method to assess clonogenic survival of irradiated cancer cells

    Methods in Cell Biology, Vol. 174, pp. 127-136

  7. Ansprechen follikulotroper Mycosis fungoides auf Capecitabin

    JDDG - Journal of the German Society of Dermatology

  8. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  9. Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy

    JCO clinical cancer informatics, Vol. 7, pp. e2200189

  10. Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study

    Frontiers in Psychology, Vol. 14

  11. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  12. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  13. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

  14. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936

  15. Clinical feasibility of combining intraoperative electron radiation therapy with minimally invasive surgery: a potential for electron-FLASH clinical development

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 429-439

  16. Co-Design and Validation of a Family Nursing Educational Intervention in Long-Term Cancer Survivorship Using Expert Judgement

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 2

  17. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

  18. Corrigendum: Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect, (Front. Oncol, (2022), 12, (1037262), 10.3389/fonc.2022.1037262)

    Frontiers in Oncology

  19. Delays to surgery following chemoradiotherapy lead to poorer oncologic outcomes in patients with localized pancreatic adenocarcinoma

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 8, pp. 428-434

  20. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13